Physician profile
Na Liu
NPI 1356732119
$891.37
in general payments reported to CMS, 2019-2025
13 companies · $84.34 in 2025
The $84.34 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2021: $18.74 · 2022: $121 · 2023: $274 · 2024: $283 · 2025: $84.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $641.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $199.17 | 2022-2025 | Doc Band |
| Glaxosmithkline, LLC. | $124.58 | 2022-2025 | Bexsero, Pediarix, Fluarix Quadrivalent |
| E.R. Squibb & Sons, L.L.C. | $110.12 | 2019 | |
| Pfizer INC. | $107.76 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $84.68 | 2023-2024 | Flumist Quadrivalent |
| Sanofi Pasteur INC. | $72.18 | 2021-2024 | |
| Biomarin Pharmaceutical INC. | $48.29 | 2023 | Voxzogo 1.2mg |
| Seqirus USA INC | $40.77 | 2023 | Flucelvax Quadrivalent |
| Merck Sharp & Dohme LLC | $29.86 | 2022 | |
| Verrica Pharmaceuticals INC. | $26.89 | 2024 | Ycanth |
| Phadia US INC. | $18.92 | 2023 | Immunocap |
| Cumberland Pharmaceuticals, INC. | $14.64 | 2024 | Kristalose |
| Kowa Pharmaceuticals America, INC. | $13.51 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Na Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.